Terms: = Liver cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
355 results:
1. Predictive factors of 90-day mortality after curative hepatic resection for hepatocellular carcinoma: a western single-center observational study.
Vaghiri S; Lehwald-Tywuschik N; Prassas D; Safi SA; Kalmuk S; Knoefel WT; Dizdar L; Alexander A
Langenbecks Arch Surg; 2024 May; 409(1):149. PubMed ID: 38698255
[TBL] [Abstract] [Full Text] [Related]
2. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study.
Boyd S; Mustamäki T; Sjöblom N; Nordin A; Tenca A; Jokelainen K; Rantapero T; Liuksiala T; Lahtinen L; Kuopio T; Kytölä S; Mäkisalo H; Färkkilä M; Arola J
Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38551383
[TBL] [Abstract] [Full Text] [Related]
3. Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis.
Cheng XF; Zhao F; Chen D; Liu FL
World J Gastroenterol; 2024 Feb; 30(7):663-672. PubMed ID: 38515943
[TBL] [Abstract] [Full Text] [Related]
4. Evolving survival gains in patients with young-onset colorectal cancer and synchronous resectable liver metastases.
Maki H; Haddad A; Lendoire M; Newhook TE; Peacock O; Bednarski BK; Konishi T; Vauthey JN; You YN
Eur J Surg Oncol; 2024 Apr; 50(4):108057. PubMed ID: 38461567
[TBL] [Abstract] [Full Text] [Related]
5. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract] [Full Text] [Related]
6. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
[TBL] [Abstract] [Full Text] [Related]
7. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
[TBL] [Abstract] [Full Text] [Related]
8. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal cancer: A Systematic Review.
Guven DC; Kavgaci G; Erul E; Syed MP; Magge T; Saeed A; Yalcin S; Sahin IH
Oncologist; 2024 May; 29(5):e580-e600. PubMed ID: 38309719
[TBL] [Abstract] [Full Text] [Related]
9. [A Case of Advanced Recurrent Rectal cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug].
Sakuma T; Shibutani M; Fukuoka T; Kasashima H; Nishiyama M; Fukui Y; Natsuki S; Nishiyama T; Maruo K; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1504-1506. PubMed ID: 38303322
[TBL] [Abstract] [Full Text] [Related]
10. [Considering Recurrence Prevention Regimen for Colorectal cancer Patients with Hyperammonemia Caused by Chemotherapy Containing 5-Fluorouracil].
Aomatsu N; Tsujio G; Aomatsu K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1851-1853. PubMed ID: 38303229
[TBL] [Abstract] [Full Text] [Related]
11. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
Stemmer A; Margalit O; Serpas V; Strauss G; Thomas J; Shah P; Tau N; Levanon K; Shacham-Shmueli E; Kopetz S; Overman M; Boursi B
Eur J Cancer; 2024 Feb; 198():113495. PubMed ID: 38157568
[TBL] [Abstract] [Full Text] [Related]
13. Local treatment of liver metastasis in a patient with advanced malignant melanoma: A case report.
Hong H; Shen L; Tan H; Wu Y; Liu Y; Fan W
J Cancer Res Ther; 2023 Dec; 19(6):1675-1679. PubMed ID: 38156937
[TBL] [Abstract] [Full Text] [Related]
14. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
15. Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience.
Ozkan M; Oflazoglu U; Yildiz Y; Güc ZG; Salman T; Ünal S; Kücükzeybek Y; Alacacioglu A
Medicine (Baltimore); 2023 Dec; 102(50):e36435. PubMed ID: 38115370
[TBL] [Abstract] [Full Text] [Related]
16. Nivolumab treatment in a patient with braf mutant advanced melanoma and liver failure with encephalopathy.
Colak R; Kapar C; Gulturk I; Yilmaz M
J Oncol Pharm Pract; 2024 Apr; 30(3):589-593. PubMed ID: 38111303
[TBL] [Abstract] [Full Text] [Related]
17. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
18. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced braf V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract] [Full Text] [Related]
19. Comparative Clinicopathologic and Genomic Analysis of Hepatocellular Neoplasm, Not Otherwise Specified, and Hepatoblastoma.
Zhou S; Sarabia SF; Estrine D; Ostrow D; Schmidt RJ; Warren M; Raca G; Shillingford N; Wang L; Pawel B; Stein JE; Biegel JA; Lopez-Terrada D; Mascarenhas L; Ji J
Mod Pathol; 2024 Feb; 37(2):100385. PubMed ID: 37992967
[TBL] [Abstract] [Full Text] [Related]
20. MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance.
Arasi MB; De Luca G; Chronopoulou L; Pedini F; Petrucci E; Flego M; Stringaro A; Colone M; Pasquini L; Spada M; Lulli V; Perrotta MC; Calin GA; Palocci C; Biffoni M; Felicetti F; Felli N
Mol Ther; 2024 Jan; 32(1):152-167. PubMed ID: 37990493
[TBL] [Abstract] [Full Text] [Related]
[Next]
